Here is a data-driven look at Aurobindo Pharma Ltd. (AUROPHARMA), covering financial performance, valuation, and shareholding trends.
Aurobindo Pharma Revenue Trend
Top-line growth continued for Aurobindo Pharma Ltd., with FY2025 revenue reaching ₹32,346 Cr — a 9.4% increase over FY2024.
Revenue compounded at 10.3% annually over 10 years for Aurobindo Pharma Ltd.. That's a strong growth rate that comfortably outpaces inflation.
A ₹32,346 Cr revenue base makes Aurobindo Pharma Ltd. a major name in the Indian pharmaceuticals sector.
With 3 straight years of revenue growth, this isn't a blip — the trajectory is clear for Aurobindo Pharma Ltd..
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹32,346 Cr | +9.4% |
| FY2024 | ₹29,559 Cr | +17.6% |
| FY2023 | ₹25,146 Cr | +5.8% |
| FY2022 | ₹23,776 Cr | -4.0% |
| FY2021 | ₹24,775 Cr | — |
View Aurobindo Pharma Ltd.'s full 10-year revenue trend with CAGR analysis →
Aurobindo Pharma Profitability
Year-over-year, net profit grew 10.0% from ₹3,169 Cr to ₹3,486 Cr in FY2025 for Aurobindo Pharma Ltd..
The company maintained its net margin at 10.8% in FY2025, roughly in line with the prior year.
Earnings per share (diluted) were ₹59.81 in FY2025, up from ₹54.16.
Is Aurobindo Pharma Undervalued
Aurobindo Pharma Ltd. shares are currently trading at ₹1,523.40.
Craytheon calculates intrinsic value using the P/E Ratio, DCF, and EPS Growth models. All three appear in the Valuation Models cards below.
Valuation Models
Aurobindo Pharma Shareholding Pattern
A stable promoter holding of 51.8% over 4 quarters suggests the management group is comfortable with its position.
Foreign institutional investors (FIIs) held 15.2% as of March 2026, up from 14.4% a year ago.
On the domestic institutional side, the holding is 25.9% as of March 2026 — down from 26.9%.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 51.8% | 15.2% | 25.9% | 7.1% |
| Dec 2025 | 51.8% | 13.9% | 27.7% | 6.5% |
| Sep 2025 | 51.8% | 14.2% | 27.6% | 6.4% |
| Jun 2025 | 51.8% | 14.4% | 26.9% | 6.9% |
Track quarterly shareholding changes for Aurobindo Pharma Ltd. →
Aurobindo Pharma Balance Sheet
Proportional view as of 23 Jul 2026. Hover blocks for details.
Assets
Liabilities & Equity
In FY2025, the total asset base came in at ₹497.85B, up 10.5% YoY from ₹450.72B.
Property, Plant & Equipment accounts for 30.5% of the total, ahead of Inventories (21.2%) and Other Assets (16.6%).
Capital structure: 65.6% equity, 16.6% debt, 17.8% operating liabilities. Over the year, debt is up 24.3% and equity is up 9.4%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 55.69B |
| Receivables | 57.46B |
| Inventories | 105.44B |
| Property, Plant & Equipment | 151.61B |
| Investments | 2.52B |
| Intangibles & Goodwill | 42.39B |
| Other Assets | 82.75B |
| Category | Value |
|---|---|
| Equity | 326.47B |
| Short-term Debt | 64.62B |
| Long-term Debt | 18.01B |
| Trade Payables | 41.89B |
| Other Liabilities | 46.86B |
Aurobindo Pharma Key Highlights
Here's the bottom line on Aurobindo Pharma Ltd. (AUROPHARMA) based on the latest available financials.
Revenue of ₹32,346 Cr in FY2025, up 9.4% year-over-year.
Long-term revenue has been compounding at 10.3% annually over 10 years.
The company is profitable, with a net margin of 10.8% and net income of ₹3,486 Cr.
Unlock Full Analysis
Get the complete view of Aurobindo Pharma Ltd. on Craytheon — 10 years of financials, three valuation models, and institutional holding trends.